Company Overview
InflaRx N.V. operates as a clinical-stage biopharmaceutical company dedicated to discovering and developing inhibitors utilizing C5a technology within the healthcare sector's biotechnology industry. This industry classification signifies that the enterprise is focused on the research and development of biological agents to treat specific medical conditions, distinguishing it from mature pharmaceutical manufacturing sectors. The company employs a workforce of 65 individuals and maintains a market capitalization of $65.92M, while reporting trailing twelve-month revenue of $29,331. These financial figures indicate that the company functions as a small-cap entity with minimal current revenue generation relative to its valuation, a characteristic often found in early-stage biotechnology firms where value is derived from pipeline potential rather than current sales volume. The extremely high price-to-sales ratio of 2247.58 further contextualizes the market's pricing of the company based on future clinical trial success and regulatory approval prospects rather than established cash flow or earnings.
Financial Health
The company reported revenue of $29,331 over the trailing twelve-month period, yet simultaneously recorded a net income of $-45,633,780 and an EBITDA of $-48,198,212. The substantial gap between the negligible revenue figure and the massive negative net income reveals a cost structure dominated by high research and development expenditures typical of clinical-stage development, where the cost of bringing a drug to market far exceeds current sales. Free cash flow stands at $-14,833,020, which indicates that the company is currently burning through capital reserves to fund its operations and development programs rather than generating liquidity from its business activities. Analysis of the three primary margin metrics shows a gross margin of 0.0%, an operating margin of 37898.3%, and a profit margin of 0.0%. The zero gross and profit margins suggest that costs of goods sold or general operating expenses are consuming the entire revenue base, while the anomalously high operating margin is a mathematical artifact resulting from the division of positive operating income by the near-zero revenue figure. The balance sheet holds $46.46M in cash against $897,916 in debt, resulting in a debt-to-equity ratio of 2.16. Despite the elevated debt-to-equity metric, the sheer volume of cash on hand suggests the balance sheet is not leveraged to a dangerous extent regarding immediate solvency, as the company holds significantly more liquid assets than liabilities. The current ratio of 4.13 indicates strong short-term liquidity, demonstrating that the company possesses more than four times the current assets necessary to cover its current liabilities. Return on Equity is -88.6% and Return on Assets is -46.0%, revealing that management effectiveness is currently measured by the rate at which the company is depleting shareholder and asset value to fund its clinical pipeline.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -1.23. The existence of a negative forward P/E alongside a missing trailing P/E implies that the market expects earnings to remain negative for the foreseeable future, preventing the calculation of a traditional multiple based on expected profitability. The price-to-book ratio is 1.37, which indicates that the market values the company at 37% above its book value, reflecting a premium assigned to the intangible assets of the clinical pipeline and intellectual property despite the lack of current earnings. Alternative valuation metrics such as the price-to-sales ratio of 2247.58 and the EV/EBITDA of -0.42 suggest that traditional valuation methods are inapplicable, as the company is trading at a multiple of revenue that is exceptionally high for a non-profitable entity. The stock's 52-week high is $1.94 and the 52-week low is $0.71, placing the current trading environment within a wide volatility band typical of small-cap biotechnology stocks. The beta of 1.53 indicates that the stock's price volatility is 53% higher than the broader market, meaning the asset will likely experience amplified movements relative to the S&P 500 during periods of market turbulence.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a pre-revenue or early-revenue entity where historical growth rates are not yet established. Since the company is not yet generating significant profits, earnings are technically not growing faster or slower than revenue in a traditional sense, as both metrics are constrained by the developmental phase of the business. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all available capital to reinvest into its drug discovery programs and clinical trials rather than distributing income to shareholders. The overall growth and income profile is defined by a reliance on external capital markets to sustain operations until the lead product candidate, vilobelimab, can potentially generate commercial revenue to support future growth.